Clinical TrialJun 2, 2026, 07:41 PM
DBV Technologies Screens First Participant in THRIVE Phase 2 Study
AI Summary
DBV Technologies announced the screening of the first participant in its THRIVE Phase 2 clinical study. This study evaluates the efficacy and safety of the VIASKIN® Peanut Patch in infants aged 6 to 12 months with peanut allergy, aiming for ad lib consumption of dietary peanut. The company believes this early, non-invasive intervention could alter the trajectory of peanut allergy in this young population, building on positive results observed in toddlers and older children.
Key Highlights
- DBV Technologies screened the first participant in its THRIVE Phase 2 clinical study.
- The study evaluates the VIASKIN® Peanut Patch in infants aged 6-12 months with peanut allergy.
- The primary goal is to assess efficacy and safety in achieving ad lib consumption of dietary peanut.
- Participants will use the patch daily for 36 months, followed by a peanut food challenge.
- The study aims to provide insights into early intervention for peanut allergy in infants.
Price Impact
More from DBVT